

# Sample-size determination and adherence in randomised controlled trials published in anaesthetic journals

M Nontshe<sup>a</sup> , S Khan<sup>a</sup>, T Mandebvu<sup>a</sup>, B Merrifield<sup>a</sup> and RN Rodseth<sup>ab\*</sup> 

<sup>a</sup>Metropolitan Department of Anaesthetics, Critical Care and Pain Management, University of KwaZulu-Natal, Pietermaritzburg, South Africa

<sup>b</sup>Outcomes Research Consortium, Cleveland Clinic, Cleveland, OH, USA

\*Corresponding author, email: [rodsethr@ukzn.ac.za](mailto:rodsethr@ukzn.ac.za)



**Background:** Sample-size calculations are critical to ensure that randomised control trials return robust and reliable results. The estimated treatment effects used in these calculations is often significantly different from the actual treatment effect and can dramatically impact trial validity.

**Methods:** This study examined sample-size calculations in randomised controlled trials designed to show superiority between two-arm parallel groups with a single primary outcome that were published in the top five anaesthetic journals for 2014 (as per Thomson Reuters impact factors). In particular, it sought to determine treatment effect estimations used in a priori sample-size calculations and compare them with actual treatment effects.

**Results:** A PubMed search identified 209 possible articles; 52 were drawn for full text review; and 28 were included in the final analysis. The relative difference between expected and actual event rates was greater than 20% in 80% of trials and greater than 50% in 44% of trials.

**Conclusions:** Unrealistic assumptions of treatment effects in randomised controlled trials published in anaesthesia journals are common. Trial sample sizes should be calculated thoughtfully and realistically and should be fully reported in both trial protocols and publications. Researchers should be aware of the opportunity cost as well as the possible dangers to patients when unrealistic assumptions are made. Where possible researchers should collaborate to achieve meaningful trial sample sizes to ensure robust clinical findings.

**Keywords:** anaesthesia, clinical trial, power calculations, sample size, treatment effect, type II error

## Introduction

Sample-size calculations are critical to ensure that randomised control trials return robust and reliable results. According to the CONSORT statement for the reporting of parallel-group randomised trials, these calculations should be reported and justified in the methods section.<sup>1</sup> Sample-size calculations establish the patient numbers required to detect clinically relevant differences between interventions. Where trials are underpowered they run the risk of failing to identify a true difference between groups, and increase the likelihood of false-positive trials—particularly when the null hypothesis is true.<sup>2</sup> In contradistinction, excessively large sample sizes run the risk of unnecessarily exposing trial subjects to risk of a new intervention.<sup>3</sup>

The primary parameters used in calculating samples sizes are: (1) the threshold chosen for the type I error (also call the level of significance or the  $p$ -value—commonly set at 5%); (2) the study power (commonly set at 80% or 90%); (3) the assumed event rate in the control group, together with some assumed standard deviation; and (4) the expected treatment effect. Assumed event rate and its standard deviation are commonly based on previously reported results, while expected treatment effect should be based on what a clinically meaningful treatment effect would be considering the clinical study environment. These assumptions are often significantly different from actual trial findings and can dramatically impact the intended power of a trial.<sup>4</sup>

In this study we aimed to examine sample-size calculations in randomised controlled trials designed to show superiority between two-arm parallel groups with a single primary outcome

that were published in the top five anaesthetic journals for 2014 (as per Thomson Reuters impact factors). In particular, we sought to determine treatment effect estimations used in a priori sample-size calculations and compare them with the actual treatment effects identified by the trial.

## Methodology

We systematically reviewed PubMed using the search terms ‘randomized controlled trials’ and ‘randomised controlled trials’ to identify all 2014 clinical randomised controlled trials published in the five anaesthetic journals with the highest impact factor as reported by Thomson Reuters. Pain-specific journals were excluded. MN screened titles and abstracts to identify candidate articles. Articles were excluded if they were not randomised, were cluster trials, included a factorial design, were non-inferiority trials, were pilot trials, made use of more than two trial arms, or reported more than one primary outcome. Articles were selected for full text review if either screener deemed them possibly eligible. Chance corrected inter-observer agreement for trial eligibility was tested using the kappa statistic.

A full text review of all candidate articles was conducted to identify eligible trials. From these eligible trials we systematically extracted the following data using a standardised data-collection sheet: author, year of publication, journal,  $p$ -value, power, expected control event rate, expected treatment effect, required sample size, actual number of recruited participants, actual control event rate, actual treatment effect, and intention-to-treat analysis. Full text screening and data extraction was conducted in duplicate by two teams, MN, SK and TM, BM, with the final data

being checked by RR. As no meta-analysis of study data was planned we did not assess trial quality or risk of bias.

For each trial the following were reported: sample-size calculation, power, alpha, two-sided testing assumption, calculated sample size, number of patients randomised, number of patients analysed, significance of trial findings, expected treatment effect, actual treatment effect, and the percentage relative difference between the estimated and actual event rates (estimated event rate minus actual event rate divided by estimated event rate). Where required, expected treatment effects reported in trial measurement units were converted to a percentage to facilitate comparison.

### Results

In 2014 the five anaesthetic journals with the highest impact factor for 2014 were Anesthesiology, Anesthesia and Analgesia, British Journal of Anaesthesia, Anaesthesia, and the Canadian Journal of Anesthesia. The PubMed search identified 209 possible articles from which 52 were drawn for full paper review. Chance corrected inter-observer agreement for trial eligibility was excellent ( $\kappa = 0.82$ ). Twenty-four trials were subsequently excluded for the following reasons: Not randomized (2),<sup>5,6</sup> pilot trial (4),<sup>7-10</sup> cross-over trial (2),<sup>11,12</sup> factorial (2),<sup>13,14</sup> multiple outcomes (5),<sup>15-19</sup> secondary analysis (4),<sup>20-23</sup> using dynamic sample size calculations (1),<sup>24</sup> non-inferiority trial (2),<sup>25,26</sup> and trial stopped early (2).<sup>27,28</sup> Trial selection process is shown in 0 1, sample-size calculation details of the 28 included trials are reported in Table 1, and a comparison of expected and actual treatment effects are provided in Table 2.

All trials reported a sample size calculation. Two trials explicitly used one-sided assumptions when calculating the sample size<sup>36,54</sup> while 13 trials did not explicitly report two-sided assumptions.<sup>33,35,37-39,42,46,48-53</sup> All studies (for brevity hereafter name of first author only given) made use of an alpha of 0.05 and power of 80%, except for Caparellei, Cheung and Yates, who used 90% power,<sup>30,31,54</sup> and Liu who used 95% power and an alpha of 0.001.<sup>43</sup> Three trials did not achieved their planned sample size.<sup>39,48,51</sup> Of note Saporito,<sup>46</sup> Stein,<sup>49</sup> and Cheung<sup>31</sup> recruited between 50% and 100% more patients than required by their sample-size calculations. In addition, Saporito *et al.* powered their trial to show superiority between two interventions but conducted a non-inferiority trial.<sup>46</sup>

All trials except for Ju reported an expected treatment effect; in addition Ju did not use the outcome that the trial was powered

on as the primary reported trial outcome.<sup>38</sup> Justification for the expected treatment effect was provided for 16 trials (57%): 12 from prior trials; 2 from pilot studies; 1 from observational data; 1 from clinical relevance. For the remaining 12 trials (43%) no justification was provided.

The relative difference between the expected and actual event rates was greater than 20% in 80% of trials and greater than 50% in 44% of trials. In six trials the actual treatment effect was in the opposite direction to that expected,<sup>34,37,40,41,51,4</sup> of which one trial had explicitly made use of a one-sided power calculation.<sup>54</sup> Eleven trials were designed using expected treatment effects greater than 20% of actual reported non-significant results,<sup>30,32,34,40,41,43,47,51,52,54,55</sup> of which seven used expected treatment results greater than 50% of actual reported.<sup>30,41,43,47,51,54,55</sup>

### Discussion

Sample-size calculations form the basis of robust evidence-based medicine. Randomised controlled trials need to be of high quality and so require, among other things, a published a priori sample size and power calculation.<sup>57</sup> This allows the trial to be reproduced and explains the researchers' underlying assumptions in designing the trial. An appropriate sample size is determined by the following design parameters: minimum expected difference (also known as the effect size), estimated measurement variability, desired statistical power, significance criterion ( $p$ -value), and whether a one- or two-tailed statistical analysis is planned.<sup>58</sup> Factors resulting in the need for a large sample size are: the desire for a highly powered study, small treatment effect, smaller  $p$ -values, the desire for narrower confidence intervals, two-tailed design of the study and increasing variability/standard difference.

Several studies in the recent past have examined power and sample-size calculations and have noted that a large percentage of randomised controlled trials are either underpowered or have no record of an a priori sample-size calculation. Further, many trials were found to have low statistical power thereby increasing the probability of a type II error.<sup>2,57</sup> Christley *et al.*, in a review of the surgical literature, noted that of 127 randomised controlled trials only half were sufficiently powered to detect large differences between treatment groups.<sup>2</sup> These underpowered studies may even have affected meta-analyses where low-powered studies with significant results have been included, especially when they have negative results. Muncer *et al.* note that by ignoring power the single-study researcher makes it




Figure 1: Trial selection process.

Table 1: Sample-size calculation characteristics of included trials

Author	Sample size calculation	Power	Alpha	Two-sided?	Sample size			
					Calculated	Randomised	Analysed	Sample size achieved?
Arab <sup>29</sup>	Yes	80%	5%	Yes	96	96	96	Yes
Cappelleri <sup>30</sup>	Yes	90%	5%	Yes	76	90	83	Yes
Cheung <sup>31</sup>	Yes	90%	5%	Yes	50	100	96	Yes
Cho <sup>32</sup>	Yes	80%	5%	Yes	78	78	78	Yes
Ferrando <sup>33</sup>	Yes	80%	5%	NS	30	30	30	Yes
Kuruba <sup>34</sup>	Yes	80%	5%	Yes	54	54	51	Yes
Horn <sup>35</sup>	Yes	80%	5%	NS	40	40	40	Yes
Hwang <sup>36</sup>	Yes	80%	5%	One-sided	62	68	66	Yes
Ilyas <sup>37</sup>	Yes	80%	5%	NS	128	128	128	Yes
Ju <sup>38</sup>	Yes	80%	5%	NS	84	100	84	Yes
Kim <sup>39</sup>	Yes	80%	5%	NS	166	184	181	Yes
Kim <sup>40</sup>	Yes	80%	5%	Yes	46	55	53	No
Landoni <sup>41</sup>	Yes	80%	5%	Yes	186	200	200	Yes
Lim <sup>42</sup>	Yes	80%	5%	NS	56	62	60	Yes
Liu <sup>43</sup>	Yes	95%	1%	Yes	288	680	601	Yes
Murphy <sup>44</sup>	Yes	80%	5%	Yes	62	70	70	Yes
Paul <sup>45</sup>	Yes	NR	5%	NR	NR	40	40	NA
Saporito <sup>46</sup>	Yes	80%	5%	NS	60	122	120	Yes
Sharma <sup>47</sup>	Yes	80%	5%	Yes	400	400	302	Yes
Sng <sup>48</sup>	Yes	80%	5%	NS	216	216	213	No
Stein <sup>49</sup>	Yes	80%	5%	NS	86	116	109	Yes
Ueki <sup>50</sup>	Yes	80%	5%	NS	34	42	37	Yes
van Loon <sup>51</sup>	Yes	80%	5%	NS	440	427	415	No
Westergaard <sup>52</sup>	No	NR	NR	NS	52	60	59	Yes
Yamamoto <sup>53</sup>	Yes	80%	5%	NS	78	90	86	Yes
Yates <sup>54</sup>	Yes	90%	5%	One-sided	202	206	202	Yes
Yoshida <sup>55</sup>	Yes	80%	5%	Yes	44	60	54	Yes
Zhang <sup>56</sup>	Yes	80%	5%	Yes	46	72	65	Yes

Note: NR—not reported; NS—not specified.

difficult to get negative results published and therefore affects meta-analysis through publication bias.<sup>59</sup>

In this analysis more than 80% of trials overestimated the treatment effect by more than 20% and 44% of trials by more than 50%. Similarly, in an analysis of internal medicine trials Charles *et al.* found significant discrepancies between expected and observed treatment effects.<sup>57</sup> The reason for these findings is unclear. It may possibly be due to overzealous estimation of the estimated parameters with a desire to lower the required sample size. This is done by first choosing a convenient study period (e.g. six months) or attainable study sample size (e.g. 100/200/300 etc. participants) and then plugging in a treatment effect that provides the desired sample size. While it is not formally necessary that the actual treatment effect should resemble the estimated treatment effect, studies designed using unrealistic treatment effects expose patients to trial risks and waste resources without the benefit of achieving a meaningful result.<sup>60,61</sup>

In this analysis 11 trials with estimated treatment effects greater than 20% of actual reported non-significant results, of which seven used expected treatment results greater than 50% of actual.

One of these trials assumed a 66% reduction in the composite of death and prolonged ICU stay but reported a 13% increase in the primary outcome,<sup>41</sup> while a second assumed a 60% decrease in the incidence of gastrointestinal morbidity but reported a 7% increase.<sup>54</sup> We would argue that the treatment effects assumed in many of these trials are unrealistic, especially considering the nature of some of the outcomes being studied. Many of these trials are therefore practically underpowered and would likely necessitate a second larger trial. It is worth noting that Yates *et al.*<sup>54</sup> made use of one-sided assumptions when calculating their sample size, but found a treatment effect in the opposite direction than expected. This highlights the danger of using one-sided sample-size assumptions in clinical research.

Trial designers do not only err by making sample sizes too small. In this analysis Saporito and Cheung doubled their sample size,<sup>31,46</sup> and Stein recruited 68% more patients than required without providing a clear motivation for doing so.<sup>49</sup> While it is appropriate to increase sample size to account for patient dropout these considerations should be made explicit in the trial protocol. Recruiting excessive patients without a reasoned rational unnecessarily exposes them to possible harm.

Table 2: Comparison of assumed and actual treatment effect in included trials

Author	Primary outcome used for sample size calculation	Treatment effect			Significant finding?
		Estimated	Estimate justification	Actual	
Arab <sup>29</sup>	Proportion of satisfactory sensory block	50% improvement	Pilot study	36% improvement	Yes
Cappelleri <sup>30</sup>	Duration of sciatic nerve block	12.5% improvement	NR	2% improvement	No
Cheung <sup>31</sup>	Change in pain score (area under the curve)	30% reduction	Previous trial	17% reduction	Yes
Cho <sup>32</sup>	Forced expiratory volume on the third postoperative day	10% improvement	Previous trial	7.5% improvement	No
Ferrando <sup>33</sup>	Oxygenation at the end of one-lung ventilation period	10% improvement	Previous trial	18% improvement	Yes
Kuruba <sup>34</sup>	Morphine consumption in the first 24 h after surgery	2.7% reduction	Observational data	2.3% increase*	No
Horn <sup>35</sup>	Neonatal core temperature	1.4% increase	Previous trial	3% increase	Yes
Hwang <sup>36</sup>	Incidence of spinal hypotension	35% reduction	Previous trial	43% reduction	Yes
Ilyas <sup>37</sup>	Time taken for successful intubation	20% reduction	Previous trial	65% increase*	Yes
Ju <sup>38</sup>	Oxygen index 30 min after one lung ventilation	NR	Pilot study	NR	Yes
Kim <sup>39</sup>	First-attempt l-gel insertion success rate	15% increase	Previous trial	13% increase	Yes
Kim <sup>40</sup>	Oropharyngeal leak pressure	20% reduction	Previous trial	5% increase*	No
Landoni <sup>41</sup>	Composite of death and prolonged ICU stay	66% reduction	NR	13% increase*	No
Lim <sup>42</sup>	Incidence of improper placement of tracheal tube	40% reduction	Previous trial	45% reduction	Yes
Liu <sup>43</sup>	Propofol or remifentanyl consumption	20% reduction	NR	6% reduction	No
Murphy <sup>44</sup>	Cerebral tissue oxygenation	4.5% increase	Previous trial	5.3% increase	Yes
Paul <sup>45</sup>	Depth of bougie insertion	NR	NR	NR	Yes
Saporito <sup>46</sup>	Incidence of unscheduled outpatient visits or readmissions	NA	NR	NA	No
Sharma <sup>47</sup>	Incidence of intrapartum fever	50% reduction	NR	5% reduction	No
Sng <sup>48</sup>	Incidence of reactive hypertension	20% reduction	Previous trial	59% reduction	Yes
Stein <sup>49</sup>	Incidence of post-dural puncture headache	57% reduction	NR	77% reduction	Yes
Ueki <sup>50</sup>	Plasma HMGB1 level	30% reduction	NR	35% reduction	Yes
van Loon <sup>51</sup>	Incidence of hypoxemia	50% reduction	NR	0.8% increase*	No
Westergaard <sup>52</sup>	Two-point difference in average pain score over 24 h	60% reduction	NR	40% reduction	No
Yamamoto <sup>53</sup>	Complete sensory block of all sciatic nerve components	62% increase	Previous trial	69% increase	Yes
Yates <sup>54</sup>	Gastrointestinal morbidity	60% decrease	NR	7% increase*	No
Yoshida <sup>55</sup>	Number of anaesthetised dermatomes 24 h after surgery	30% increase	Clinical relevance	0% increase	No
Zhang <sup>56</sup>	Length of recovery room stay	30% decrease	NR	20% decrease	Yes

Notes: NA—not applicable; NR—not reported.

\*Direction of treatment effect opposite of expected.

Traditionally sample-size calculations are performed during the design phase of a trial and are rarely revisited. A trial excluded during full text review provides a different perspective on this approach. Mercier *et al.* initially assumed a 35% event rate in the baseline group with a 20% treatment effect.<sup>24</sup> The authors planned a sample-size recalculation once 50% of patients had been randomised to ensure that adequate power was achieved—the trial *p*-value was adjusted to correct for multiple testing. Adopting this model of trial design ensures that the trial is adequately powered and provides reliable results.

Clinical medicine faces the challenge of dealing with a flood of inconclusive research and questions being asked of how we go about improving the reliability of our research.<sup>62,63</sup> Locally, South African clinical trainees are producing a multitude of small underpowered studies in an attempt to fulfil regulator training requirements.<sup>64</sup> To address these problems researchers should be aware of the opportunity cost as well as the possible dangers to patients when robust research methodology is not followed. Trial sample sizes should be calculated thoughtfully and realistically and should be fully reported in both trial protocols and publications. Where possible researchers should aim to collaborate so as to achieve meaningful trial sample sizes and so ensure robust clinical findings.

**Disclosure statement** – No potential conflict of interest was reported by the authors.

#### ORCID

M Nontshe  <http://orcid.org/0000-0003-0879-3722>

RN Rodseth  <http://orcid.org/0000-0002-3779-7805>

#### References

- Schulz KF, Altman DG, Moher D, et al. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010;340(mar23 1):c332–c332. <https://doi.org/10.1136/bmj.c332>
- Christley RM. Power and error: increased risk of false positive results in underpowered studies. *The Open Epidemiology Journal*. 2010;3(1):16–9. <https://doi.org/10.2174/1874297101003010016>
- Altman DG. Statistics and ethics in medical research: Ill how large a sample? *Br Med J*. 1980;281(6251):6–8. <https://doi.org/10.1136/bmj.281.6251.1336>
- Schulz KF, Grimes DA. Sample size calculations in randomised trials: mandatory and mystical. *Lancet*. 2005;365(9467):1348–53. [https://doi.org/10.1016/S0140-6736\(05\)61034-3](https://doi.org/10.1016/S0140-6736(05)61034-3)
- Zeidan AM, Salem MR, Mazoit JX, et al. The effectiveness of cricoid pressure for occluding the esophageal entrance in anesthetized and paralyzed patients: an experimental and observational glidescope study. *Anesth Analg*. 2014;118(3):580–6. <https://doi.org/10.1213/ANE.0000000000000068>
- MacDonald N, Ahmad T, Mohr O, et al. Dynamic preload markers to predict fluid responsiveness during and after major gastrointestinal surgery: an observational substudy of the OPTIMISE trial. *Br J Anaesth*. 2015;114(4):598–604. <https://doi.org/10.1093/bja/aeu398>
- Short TG, Leslie K, Campbell D, et al. A pilot study for a prospective, randomized, double-blind trial of the influence of anesthetic depth on long-term outcome. *Anesth Analg*. 2014;118(5):981–6. <https://doi.org/10.1213/ANE.0000000000000209>
- Kok WF, van Harten AE, Koene BM, et al. A pilot study of cerebral tissue oxygenation and postoperative cognitive dysfunction among patients undergoing coronary artery bypass grafting randomised to surgery with or without cardiopulmonary bypass\*. *Anaesthesia*. 2014;69(6):613–22. <https://doi.org/10.1111/anae.12634>
- Wijesundera DN, Choi PT, Badner NH, et al. A randomized feasibility trial of clonidine to reduce perioperative cardiac risk in patients on chronic beta-blockade: the EPIC study. *Canadian Journal of Anesthesia/Journal canadien d'anesthésie*. 2014;61(11):995–1003. <https://doi.org/10.1007/s12630-014-0226-6>
- Bidd H, Dulai R, Edelman N, et al. The effect of intra-operative passive movement therapy on non-surgical site pain after breast reconstructive surgery: a preliminary study. *Anaesthesia*. 2014;69(8):872–7. <https://doi.org/10.1111/anae.12729>
- Bendtsen TF, Pedersen EM, Haroutounian S, et al. The suprasacral parallel shift vs lumbar plexus blockade with ultrasound guidance in healthy volunteers—a randomised controlled trial. *Anaesthesia*. 2014;69(11):1227–40. <https://doi.org/10.1111/anae.12753>
- Hashimoto Y, Asai T, Arai T, et al. Effect of cricoid pressure on placement of the l-gel™: a randomised study. *Anaesthesia*. 2014;69(8): 878–82. <https://doi.org/10.1111/anae.12731>
- Lindholm EE, Aune E, Frøland G, et al. Analysis of transthoracic echocardiographic data in major vascular surgery from a prospective randomised trial comparing sevoflurane and fentanyl with propofol and remifentanyl anaesthesia. *Anaesthesia*. 2014;69(6):558–72. <https://doi.org/10.1111/anae.12604>
- Sohn LE, Jagannathan N, Sequera-Ramos L, et al. A randomised comparison of free-handed vs air-Q-assisted fiberoptic-guided tracheal intubation in children < 2 years of age. *Anaesthesia*. 2014;69(7):723–8. <https://doi.org/10.1111/anae.2014.69.issue-7>
- de Man FR, Erwtaman M, van Groeningen D, et al. The effect of audible alarms on anaesthesiologists' response times to adverse events in a simulated anaesthesia environment: a randomised trial. *Anaesthesia*. 2014;69(6):598–603. <https://doi.org/10.1111/anae.12640>
- Adelborg K, Al-Mashhadi RH, Nielsen LH, et al. A randomised crossover comparison of manikin ventilation through Soft Seal(R), i-gel and AuraOnce supraglottic airway devices by surf lifeguards. *Anaesthesia*. 2014;69(4):343–7. <https://doi.org/10.1111/anae.12545>
- Yin J, Wang SL, Liu XB. The effects of general anaesthesia on memory in children: a comparison between propofol and sevoflurane. *Anaesthesia*. 2014;69(2):118–23. <https://doi.org/10.1111/anae.2014.69.issue-2>
- Englberger L, Dietrich W, Eberle B, et al. A novel blood-sparing agent in cardiac surgery? First in-patient experience with the synthetic serine protease inhibitor MDCO-2010: a phase II, randomized, double-blind, placebo-controlled study in patients undergoing coronary artery bypass grafting with cardiopulmonary bypass. *Anesth Analg*. 2014;119(1):16–25. <https://doi.org/10.1213/ANE.0000000000000218>
- Kancir AS, Pleckaitiene L, Hansan TB, et al. Lack of nephrotoxicity by 6% hydroxyethyl starch 130/0.4 during hip arthroplasty: a randomized controlled trial. *Anesthesiology*. 2014;121(5):948–58. <https://doi.org/10.1097/ALN.0000000000000413>
- Brown CH, Azman AS, Gottschalk A, et al. Sedation depth during spinal anesthesia and survival in elderly patients undergoing hip fracture repair. *Anesth Analg*. 2014;118(5):977–80. <https://doi.org/10.1213/ANE.0000000000000157>
- Meyhoff CS, Jorgensen LN, Wetterslev J, et al. Risk of new or recurrent cancer after a high perioperative inspiratory oxygen fraction during abdominal surgery. *Br J Anaesth*. 2014;113(Suppl 1):i74–81. <https://doi.org/10.1093/bja/aeu110>
- Singh PP, Lemanu DP, Taylor MH, et al. Association between preoperative glucocorticoids and long-term survival and cancer recurrence after colectomy: follow-up analysis of a previous randomized controlled trial. *Br J Anaesth*. 2014;113(Suppl 1):i68–73. <https://doi.org/10.1093/bja/aeu577>
- Whitlock EL, Torres BA, Lin N, et al. Postoperative delirium in a substudy of cardiothoracic surgical patients in the BAG-RECALL clinical trial. *Anesth Analg*. 2014;118(4):809–17. <https://doi.org/10.1213/ANE.000000000000028>
- Mercier FJ, Diemunsch P, Ducloy-Bouthors AS, et al. 6% Hydroxyethyl starch (130/0.4) vs Ringer's lactate preloading before spinal anaesthesia for Caesarean delivery: the randomized, double-blind, multicentre CAESAR trial. *Br J Anaesth*. 2014;113(3):459–67. <https://doi.org/10.1093/bja/aeu103>
- Twersky RS, Goel V, Narayan P, et al. The risk of hypertension after preoperative discontinuation of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists in ambulatory and same-day admission patients. *Anesth Analg*. 2014;118(5):938–44. <https://doi.org/10.1213/ANE.0000000000000076>

26. Yang CW, Jung SM, Kwon HU, et al. A comparison of posterior and medial cord stimulation for neurostimulation-guided vertical infraclavicular block: a randomized noninferiority clinical trial. *Anesth Analg.* 2014;118(4):874–8. <https://doi.org/10.1213/ANE.0000000000000143>
27. Silbert BS, Evered LA, Scott DA. Incidence of postoperative cognitive dysfunction after general or spinal anaesthesia for extracorporeal shock wave lithotripsy. *Br J Anaesth.* 2014;113(5):784–91. <https://doi.org/10.1093/bja/aeu163>
28. Wadhwa A, Kabon B, Fleischmann E, et al. Supplemental postoperative oxygen does not reduce surgical site infection and major healing-related complications from bariatric surgery in morbidly obese patients: a randomized, blinded trial. *Anesth Analg.* 2014;119(2):57–65. <https://doi.org/10.1213/ANE.0000000000000318>
29. Arab SA, Alharbi MK, Nada EM, et al. Ultrasound-guided supraclavicular brachial plexus block: single versus triple injection technique for upper limb arteriovenous access surgery. *Anesth Analg.* 2014;118(5):1120–5. <https://doi.org/10.1213/ANE.0000000000000155>
30. Cappelleri G, Ambrosoli AL, Turconi S, et al. Effect of local anesthetic dilution on the onset time and duration of double-injection sciatic nerve block: a prospective, randomized, blinded evaluation. *Anesth Analg.* 2014;119(2):489–93. <https://doi.org/10.1213/ANE.0000000000000293>
31. Cheung CW, Qiu Q, Ying AC, et al. The effects of intra-operative dexmedetomidine on postoperative pain, side-effects and recovery in colorectal surgery. *Anaesthesia.* 2014;69(11):1214–21. <https://doi.org/10.1111/anae.12759>
32. Cho YJ, Ryu H, Lee J, et al. A randomised controlled trial comparing incentivespirometrywiththeAcapella(R)deviceforphysiotherapyafter thoracoscopic lung resection surgery. *Anaesthesia.* 2014;69(8):891–8. <https://doi.org/10.1111/anae.12750>
33. Ferrando C, Mugarra A, Gutierrez A, et al. Setting individualized positive end-expiratory pressure level with a positive end-expiratory pressure decrement trial after a recruitment maneuver improves oxygenation and lung mechanics during one-lung ventilation. *Anesth Analg.* 2014;118(3):657–65. <https://doi.org/10.1213/ANE.0000000000000105>
34. Gulyam Kuruba SM, Mukhtar K, Singh SK. A randomised controlled trial of ultrasound-guided transversus abdominis plane block for renal transplantation. *Anaesthesia.* 2014;69(11):1222–6. <https://doi.org/10.1111/anae.12704>
35. Horn EP, Bein B, Steinfath M, et al. The incidence and prevention of hypothermia in newborn bonding after cesarean delivery: a randomized controlled trial. *Anesth Analg.* 2014;118(5):997–1002. <https://doi.org/10.1213/ANE.0000000000000160>
36. Hwang J, Min S, Kim C, et al. Prophylactic glycopyrrolate reduces hypotensive responses in elderly patients during spinal anaesthesia: a randomized controlled trial. *Canadian Journal of Anesthesia/Journal canadien d'anesthésie.* 2014;61(1):32–8. <https://doi.org/10.1007/s12630-013-0064-y>
37. Ilyas S, Symons J, Bradley WP, et al. A prospective randomised controlled trial comparing tracheal intubation plus manual in-line stabilisation of the cervical spine using the Macintosh laryngoscope vs the McGrath (R) Series 5 videolaryngoscope. *Anaesthesia.* 2014;69(12):1345–50. <https://doi.org/10.1111/anae.2014.69.issue-12>
38. Ju NY, Gao H, Huang W, et al. Therapeutic effect of inhaled budesonide (Pulmicort® Turbuhaler) on the inflammatory response to one-lung ventilation. *Anaesthesia.* 2014;69(1):14–23. <https://doi.org/10.1111/anae.12479>
39. Kim HC, Yoo DH, Kim HJ, et al. A prospective randomised comparison of two insertion methods for i-gel placement in anaesthetised paralysed patients: standard vs. rotational technique. *Anaesthesia.* 2014;69(7):729–34. <https://doi.org/10.1111/anae.2014.69.issue-7>
40. Kim MS, Oh JT, Min JY, et al. A randomised comparison of the i-gel and the Laryngeal Mask Airway Classic in infants. *Anaesthesia.* 2014;69(4):362–7. <https://doi.org/10.1111/anae.12592>
41. Landoni G, Guarracino F, Cariello C, et al. Volatile compared with total intravenous anaesthesia in patients undergoing high-risk cardiac surgery: a randomized multicentre study. *Br J Anaesth.* 2014;113(6):955–63. <https://doi.org/10.1093/bja/aeu290>
42. Lim CW, Min SW, Kim CS, et al. The use of a nasogastric tube to facilitate nasotracheal intubation: a randomised controlled trial. *Anaesthesia.* 2014;69(6):591–7. <https://doi.org/10.1111/anae.12627>
43. Liu N, Le Guen M, Boichut N, et al. Nitrous oxide does not produce a clinically important sparing effect during closed-loop delivered propofol-remifentanyl anaesthesia guided by the bispectral index: a randomized multicentre study. *Br J Anaesth.* 2014;112(5):842–51. <https://doi.org/10.1093/bja/aet479>
44. Murphy GS, Szokol JW, Avram MJ, et al. Effect of ventilation on cerebral oxygenation in patients undergoing surgery in the beach chair position: a randomized controlled trial. *Br J Anaesth.* 2014;113(4):618–27. <https://doi.org/10.1093/bja/aeu109>
45. Paul A, Gibson AA, Robinson OD, et al. The traffic light bougie: a study of a novel safety modification. *Anaesthesia.* 2014;69(3):214–8. <https://doi.org/10.1111/anae.12522>
46. Saporito A, Sturini E, Borgeat A, et al. The effect of continuous popliteal sciatic nerve block on unplanned postoperative visits and readmissions after foot surgery—a randomised, controlled study comparing day-care and inpatient management. *Anaesthesia.* 2014;69(11):1197–205. <https://doi.org/10.1111/anae.12710>
47. Sharma SK, Rogers BB, Alexander JM, et al. A randomized trial of the effects of antibiotic prophylaxis on epidural-related fever in labor. *Anesth Analg.* 2014;118(3):604–10. <https://doi.org/10.1213/ANE.0b013e3182a5d539>
48. Sng BL, Tan HS, Sia AT. Closed-loop double-vasopressor automated system vs manual bolus vasopressor to treat hypotension during spinal anaesthesia for caesarean section: a randomised controlled trial. *Anaesthesia.* 2014;69(1):37–45. <https://doi.org/10.1111/anae.12460>
49. Stein MH, Cohen S, Mohiuddin MA, et al. Prophylactic vs therapeutic blood patch for obstetric patients with accidental dural puncture—a randomised controlled trial. *Anaesthesia.* 2014;69(4):320–6. <https://doi.org/10.1111/anae.12562>
50. Ueki M, Kawasaki T, Habe K, et al. The effects of dexmedetomidine on inflammatory mediators after cardiopulmonary bypass. *Anaesthesia.* 2014;69(7):693–700. <https://doi.org/10.1111/anae.2014.69.issue-7>
51. van Loon K, van Rheineck Leyssius AT, van Zaane B, et al. Capnography during deep sedation with propofol by nonanesthesiologists: a randomized controlled trial. *Anesth Analg.* 2014;119(1):49–55. <https://doi.org/10.1213/ANE.0b013e3182a1f0a2>
52. Westergaard B, Jensen K, Lenz K, et al. A randomised controlled trial of ultrasound-guided blockade of the saphenous nerve and the posterior branch of the obturator nerve for postoperative analgesia after day-case knee arthroscopy. *Anaesthesia.* 2014;69(12):1337–44. <https://doi.org/10.1111/anae.2014.69.issue-12>
53. Yamamoto H, Sakura S, Wada M, et al. A prospective, randomized comparison between single- and multiple-injection techniques for ultrasound-guided subgluteal sciatic nerve block. *Anesth Analg.* 2014;119(6):1442–8. <https://doi.org/10.1213/ANE.0000000000000462>
54. Yates DR, Davies SJ, Milner HE, et al. Crystalloid or colloid for goal-directed fluid therapy in colorectal surgery. *Br J Anaesth.* 2014;112(2):281–9. <https://doi.org/10.1093/bja/aet307>
55. Yoshida T, Fujiwara T, Furutani K, et al. Effects of ropivacaine concentration on the spread of sensory block produced by continuous thoracic paravertebral block: a prospective, randomised, controlled, double-blind study. *Anaesthesia.* 2014;69(3):231–9. <https://doi.org/10.1111/anae.12531>
56. Zhang Q, Gao Z, Wang H, et al. The effect of pre-treatment with transcutaneous electrical acupoint stimulation on the quality of recovery after ambulatory breast surgery: a prospective, randomised controlled trial. *Anaesthesia.* 2014;69(8):832–9. <https://doi.org/10.1111/anae.12639>
57. Charles P, Giraudeau B, Dechartres A, et al. Reporting of sample size calculation in randomised controlled trials: review. *BMJ.* 2009;338(may 12 1):b1732–b1732. <https://doi.org/10.1136/bmj.b1732>
58. Eng J. Sample size estimation: how many individuals should be studied? *Radiology.* 2003;227(2):309–13. <https://doi.org/10.1148/radiol.2272012051>
59. Muncer S, Taylor S, Craigie M. Power dressing and meta-analysis: incorporating power analysis into meta-analysis. *J Adv Nurs.* 2002;38(3):274–80. <https://doi.org/10.1046/j.1365-2648.2002.02177.x>

60. Bosomprah S. Sample size calculation for multicentre efficacy trials of blood-stage malaria antigens. *Malar J.* 2013(1);12:253. <https://doi.org/10.1186/1475-2875-12-253>
61. Altman DG. Statistics and ethics in medical research. *BMJ.* 1980;281(6521):1336–8. <https://doi.org/10.1136/bmj.281.6251.1336>
62. Caplan AL. The problem of publication-pollution denialism. *Mayo Clin Proc.* 2015;90(5):565–6. <https://doi.org/10.1016/j.mayocp.2015.02.017>
63. Horton R. Offline: what is medicine's 5 sigma. *Lancet.* 2015;385(9976):1380. [https://doi.org/10.1016/S0140-6736\(15\)60696-1](https://doi.org/10.1016/S0140-6736(15)60696-1)
64. Biccadd BM, Dyer RA, Swanevelder JL, et al. Is the HPCSA requirement for a research dissertation for specialist registration the best option? *Southern African Journal of Anaesthesia and Analgesia.* 2017;23(4): 4–6.

Received: 17-11-2017 Accepted: 07-02-2018